PPARγ agonists attenuate proliferation and modulate Wnt/β-catenin signalling in melanoma cells

International Journal of Biochemistry and Cell Biology

Volumn 41, Issue 4, 2009, Pages 844-852

  Smith, Aaron G ^a   Beaumont, Kimberley A ^a   Smit, Darren J ^a   Thurber, Amy E ^a   Cook, Anthony L ^a   Boyle, Glen M ^b   Parsons, Peter G ^b   Sturm, Richard A ^a   Muscat, George E O ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Beta catenin; Melanoma; Nuclear receptor; PPAR

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA CATENIN; CELL NUCLEUS RECEPTOR; COMPLEMENTARY DNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SMALL INTERFERING RNA; WNT PROTEIN; ANTINEOPLASTIC AGENT; CHROMAN DERIVATIVE; HALOFENATE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TROGLITAZONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ATTENUATION; CANCER CELL; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; DNA SYNTHESIS; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOMODULATION; MELANOMA CELL; PLASMID; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL GROWTH; CELL STRAIN COS1; CERCOPITHECUS; DRUG EFFECT; DRUG POTENTIATION; GENETICS; MELANOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BETA CATENIN; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHROMANS; COS CELLS; HALOFENATE; HUMANS; MELANOMA; PPAR GAMMA; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES; WNT PROTEINS;

EID: 59649089249     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2008.08.037     Document Type: Article

References (57)

1. Allen T., Zhang F., Moodie S.A., Clemens L.E., Smith A., Gregoire F., et al. Halofenate is a selective peroxisome proliferator-activated receptor {gamma} modulator with antidiabetic activity. Diabetes 55 (2006) 2523-2533
2. Aronow W.S., Vicario M.D., Moorthy K., King J., Vawter M., and Papageorge's N.P. Long-term efficacy of halofenate on serum triglyceride levels. Curr Ther Res Clin Exp 18 (1975) 855-861
3. Balint B.L., and Nagy L. Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. Endocr Metab Immune Disord Drug Targets 6 (2006) 33-43
4. Beaumont K.A., Newton R.A., Smit D.J., Leonard J.H., Stow J.L., and Sturm R.A. Altered cell surface expression of human MC1R variant receptor alleles associated with red hair and skin cancer risk. Hum Mol Genet 14 (2005) 2145-2154
5. Cook A.L., Donatien P.D., Smith A.G., Murphy M., Jones M.K., Herlyn M., et al. Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest Dermatol 121 (2003) 1150-1159
6. Eisen T., Easty D.J., Bennett D.C., and Goding C.R. The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11 (1995) 2157-2164
7. Feldman E.B., Gluck F.B., and Carter A.C. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia. J Clin Pharmacol 18 (1978) 241-248
8. Freudlsperger C., Moll I., Schumacher U., and Thies A. Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro. Anticancer Drugs 17 (2006) 325-332
9. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
10. Girnun G.D., Smith W.M., Drori S., Sarraf P., Mueller E., Eng C., et al. APC-dependent suppression of colon carcinogenesis by PPARgamma. Proc Natl Acad Sci USA 99 (2002) 13771-13776
11. Goding C., and Meyskens Jr. F.L. Microphthalmic-associated transcription factor integrates melanocyte biology and melanoma progression. Clin Cancer Res 12 (2006) 1069-1073
12. Goding C.R. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 14 (2000) 1712-1728
13. Goodall J., Martinozzi S., Dexter T.J., Champeval D., Carreira S., Larue L., et al. Brn-2 expression controls melanoma proliferation and is directly regulated by beta-catenin. Mol Cell Biol 24 (2004) 2915-2922
14. Goodall J., Wellbrock C., Dexter T.J., Roberts K., Marais R., and Goding C.R. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24 (2004) 2923-2931
15. Grabacka M., Placha W., Urbanska K., Laidler P., Plonka P.M., and Reiss K. PPAR gamma regulates MITF and beta-catenin expression and promotes a differentiated phenotype in mouse melanoma S91. Pigment Cell Melanoma Res 21 (2008) 388-396
16. Grommes C., Landreth G.E., and Heneka M.T. Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol 5 (2004) 419-429
17. Grossman D., and Altieri D.C. Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20 (2001) 3-11
18. Gurnell M., Wentworth J.M., Agostini M., Adams M., Collingwood T.N., Provenzano C., et al. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis. J Biol Chem 275 (2000) 5754-5759
19. He B., You L., Uematsu K., Xu Z., Lee A.Y., Matsangou M., et al. A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia 6 (2004) 7-14
20. Helmbach H., Rossmann E., Kern M.A., and Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 93 (2001) 617-622
21. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
22. Kim K.R., Choi H.N., Lee H.J., Baek H.A., Park H.S., Jang K.Y., et al. A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol Rep 18 (2007) 825-832
23. Kolligs F.T., Hu G., Dang C.V., and Fearon E.R. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol 19 (1999) 5696-5706
24. Larue L., and Delmas V. The WNT/Beta-catenin pathway in melanoma. Front Biosci 11 (2006) 733-742
25. Levy C., Khaled M., and Fisher D.E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 12 (2006) 406-414
26. Liu J., Wang H., Zuo Y., and Farmer S.R. Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin. Mol Cell Biol 26 (2006) 5827-5837
27. Liu Y., Meng Y., Liu H., Li J., Fu J., Liu Y., et al. Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line a375. Med Oncol 23 (2006) 393-402
28. Lowell B.B. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99 (1999) 239-242
29. Lu D., Cottam H.B., Corr M., and Carson D.A. Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci USA 102 (2005) 18567-18571
30. Magenta G., Borenstein X., Rolando R., and Jasnis M.A. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer 8 (2008) 47
31. Maxwell M.A., Cleasby M.E., Harding A., Stark A., Cooney G.J., and Muscat G.E. Nur77 regulates lipolysis in skeletal muscle cells. Evidence for cross-talk between the beta-adrenergic and an orphan nuclear hormone receptor pathway. J Biol Chem 280 (2005) 12573-12584
32. Michalik L., Desvergne B., and Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4 (2004) 61-70
33. Moon R.T., Kohn A.D., De Ferrari G.V., and Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5 (2004) 691-701
34. Morin P.J. Beta-catenin signaling and cancer. Bioessays 21 (1999) 1021-1030
35. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983) 55-63
36. Mossner R., Schulz U., Kruger U., Middel P., Schinner S., Fuzesi L., et al. Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma. J Invest Dermatol 119 (2002) 576-582
37. Mulholland D.J., Dedhar S., Coetzee G.A., and Nelson C.C. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know?. Endocr Rev 26 (2005) 898-915
38. Myers S.A., Wang S.C., and Muscat G.E. The chicken ovalbumin upstream promoter-transcription factors modulate genes and pathways involved in skeletal muscle cell metabolism. J Biol Chem 281 (2006) 24149-24160
39. Nunez N.P., Liu H., and Meadows G.G. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett 236 (2006) 133-141
40. Placha W., Gil D., Dembinska-Kiec A., and Laidler P. The effect of PPARgamma ligands on the proliferation and apoptosis of human melanoma cells. Melanoma Res 13 (2003) 447-456
41. Rosentstock J., Flores-Lozano F., Schwartz S., Gonzales-Galvez G., and Karpf D. MBX-102: a novel non-TZD insulin sensitiser that improves glycemic control without causing wirght gain in patients with type 2 diabeted T2DM) on concomitant insulin therapy. Diabetes 54 (2005) A11 [Abstract]
42. Sawai H., Liu J., Reber H.A., Hines O.J., and Eibl G. Activation of peroxisome proliferator-activated receptor-gamma decreases pancreatic cancer cell invasion through modulation of the plasminogen activator system. Mol Cancer Res 4 (2006) 159-167
43. Sears D.D., Hsiao A., Ofrecio J.M., Chapman J., He W., and Olefsky J.M. Selective modulation of promoter recruitment and transcriptional activity of PPARgamma. Biochem Biophys Res Commun 364 (2007) 515-521
44. Semple R.K., Chatterjee V.K., and O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 116 (2006) 581-589
45. Sharma C., Pradeep A., Pestell R.G., and Rana B. Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes. J Biol Chem 279 (2004) 16927-16938
46. Sharma C., Pradeep A., Wong L., Rana A., and Rana B. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem 279 (2004) 35583-35594
47. Smalley K.S., and Herlyn M. Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci 1059 (2005) 16-25
48. Smit D.J., Smith A.G., Parsons P.G., Muscat G.E., and Sturm R.A. Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors. Eur J Biochem 267 (2000) 6413-6422
49. Smith A.G., Brightwell G., Smit S.E., Parsons P.G., and Sturm R.A. Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction. Melanoma Res 8 (1998) 2-10
50. Soengas M.S., and Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 22 (2003) 3138-3151
51. Sturm R.A., O'Sullivan B.J., Thomson J.A., Jamshidi N., Pedley J., and Parsons P.G. Expression studies of pigmentation and POU-domain genes in human melanoma cells. Pigment Cell Res 7 (1994) 235-240
52. Thomson J.A., Murphy K., Baker E., Sutherland G.R., Parsons P.G., Sturm R.A., et al. The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 11 (1995) 691-700
53. Vance K.W., and Goding C.R. The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 17 (2004) 318-325
54. Weeraratna A.T. A Wnt-er wonderland--the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev 24 (2005) 237-250
55. Widlund H.R., Horstmann M.A., Price E.R., Cui J., Lessnick S.L., Wu M., et al. Beta-catenin-induced melanoma growth requires the downstream target microphthalmia-associated transcription factor. J Cell Biol 158 (2002) 1079-1087
56. You L., He B., Xu Z., Uematsu K., Mazieres J., Fujii N., et al. An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 64 (2004) 5385-5389
57. You L., He B., Xu Z., Uematsu K., Mazieres J., Mikami I., et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23 (2004) 6170-6174